Dublin, Nov. 04, 2025 (GLOBE NEWSWIRE) -- The "Europe Liver Disease Therapeutic Market Forecast 2025" has been added to ResearchAndMarkets.com's offering.
The Europe Liver Disease Therapeutic Market is expected to grow from US$ 4.34 billion in 2024 to US$ 8.29 billion by 2033, at a CAGR of 7.44% from 2025 to 2033. The rising incidence of liver-related diseases, development in therapeutic treatments, and an increase in awareness about liver health are major drivers for the market's sustained growth in the healthcare industry of Europe.
Rising aging population and the rise of non-alcoholic fatty liver disease (NAFLD) have further driven demand for advanced and efficient therapies. Governmental institutions and healthcare organizations in Europe are actively encouraging early diagnosis and timely treatment, thus driving the uptake of liver disease therapeutics. Additionally, pharma innovations and clinical trials keep accelerating therapy effects, rendering these therapies more accessible and effective. Liver disease therapeutics, therefore, have high importance and stable growth in Europe's healthcare.
Europe is among the leading markets for liver disease therapy drugs, fueled by staggering figures that show liver cirrhosis alone is responsible for as many as 170,000 deaths every year on the continent. The increasing incidence of liver conditions-from fatty liver disease to cirrhosis and hepatitis-acts as a strong driver of expansion for the European liver disease therapy market. This concerning development is further fueled by lifestyle factors, such as rising obesity rates, growing alcohol consumption, and the transmission of viral infections, that all contribute to compromised liver health. Governments and healthcare institutions, in turn, are increasing their emphasis on early detection and quality treatment, thus driving demand for novel and advanced therapeutic interventions across the region.
Recent advances in medical research and pharmaceutical development have brought with them a new dawn of more effective and more secure treatments for liver disease, greatly improving the care of patients. Advances in antiviral drugs, the fast-emerging area of immunotherapy, and improvements in regenerative medicine - most notably through new stem cell therapeutic techniques - are bringing about revolutionary gains in patient outcomes. These advances are not only fostering improved health but driving the incorporation of liver disease therapeutics into Europe's healthcare systems, thus driving the growth of the market.
In a remarkable development, the European Commission approved conditional in October 2024 Iqirvo (elafibranor) 80mg tablets for the specific treatment of primary biliary cholangitis (PBC). This is to be administered in combination with ursodeoxycholic acid (UDCA) and represents hope for better management of this difficult disease and highlights the continued advancements in liver disease treatments.
Governments in Europe are proactively implementing extensive health programs focused on decreasing liver disease-related mortality rates considerably. All such programs place significant value on early diagnosis and timely intervention, indicating a strong resolve to enhance public health. In support of these programs, more funding has been devoted to research, publicity campaigns, and healthcare infrastructure upgrades, making more effective therapeutic options easily accessible. These forward-looking steps are proving to be a vital part of developing a strong growth path for the therapeutic market for liver disease in the continent.
In February 2024, a groundbreaking research project at the Hanover Medical School (MHH) in the departments of Hepatology, Infectiology, and Endocrinology will venture into the promising future of RNA as a new therapy option for liver diseases. This pioneering study aims to explore particular RNA structures that can be exploited as therapeutic targets to manage the course of liver fibrosis and Metabolic Associated Steatotic Hepatitis (MASH). The ambitious initiative has received significant funding from the Boehringer Ingelheim Foundation, which is committing around £500,000 over three years under its Rise Up! program, aimed at promoting cutting-edge basic research in medicine.
The economic burdens brought about by sophisticated treatments for liver disease, including a variety of therapies like antiviral drugs, cutting-edge immunotherapies, and intricate liver transplantation procedures, are significantly high. These exorbitant expenses can cause a huge strain on healthcare systems, generally limiting access for patients, particularly in countries with limited healthcare funding. This financial burden may dampen market expansion, especially in areas where insurance coverage is low or government assistance is not available, leading to a cycle where most people do not have access to the critical care they require.
Various liver diseases tend to advance quietly, with few to no symptoms until they are advanced. This is the factor responsible for a delay in both diagnosis and treatment, hence making patient outcomes complicated. Despite numerous campaigns for raising awareness at the public and professional levels, the numbers of early detection cases in many parts of Europe are still unacceptably low. This is a recurring problem that greatly hampers the efficacy of therapeutic interventions since dealing with advanced liver disease is more complicated, lengthy, and costly. Therefore, this kind of situation also inhibits the development of the market, restraining potential for innovation and enhancement in managing the liver's health.
Key Attributes
| Report Attribute | Details |
| No. of Pages | 200 |
| Forecast Period | 2024 - 2033 |
| Estimated Market Value (USD) in 2024 | $4.34 Billion |
| Forecasted Market Value (USD) by 2033 | $8.29 Billion |
| Compound Annual Growth Rate | 7.4% |
| Regions Covered | Europe |
Key Topics Covered
1. Introduction
2. Research & Methodology
3. Executive Summary
4. Market Dynamics
4.1 Growth Drivers
4.2 Challenges
5. Europe Liver Disease Therapeutic Market
5.1 Historical Market Trends
5.2 Market Forecast
6. Market Share Analysis
6.1 Therapy Type
6.2 Disease Type
6.3 End Users
6.4 Country
7. Therapy Type
7.1 Anti-Rejection Drugs/Immunosuppressants
7.2 Chemotherapy Drugs
7.3 Targeted therapy
7.4 Vaccines
7.5 Immunoglobulins
7.6 Corticosteroids
7.7 Anti-Viral Drugs
8. Disease Type
8.1 Non-alcoholic Fatty Liver Disease (NAFLD)
8.2 Viral Hepatitis (B, C, D)
8.3 Alcoholic Liver Disease (ALD)
8.4 Autoimmune Liver Disease (ALD)
9. End Users
9.1 Hospitals
9.2 Laboratories
9.3 Others
10. Country
10.1 France
10.2 Germany
10.3 Italy
10.4 Spain
10.5 United Kingdom
10.6 Belgium
10.7 Netherlands
10.8 Russia
10.9 Poland
10.10 Greece
10.11 Norway
10.12 Romania
10.13 Portugal
10.14 Rest of Europe
11. Value Chain Analysis
12. Porter's Five Forces Analysis
12.1 Bargaining Power of Buyers
12.2 Bargaining Power of Suppliers
12.3 Degree of Competition
12.4 Threat of New Entrants
12.5 Threat of Substitutes
13. SWOT Analysis
13.1 Strength
13.2 Weakness
13.3 Opportunity
13.4 Threats
14. Market Outlook and Opportunities
14.1 Emerging Technologies
14.2 Future Market Trends
14.3 Investment Opportunities
15. Pricing Benchmark Analysis
16. Key Players Analysis
16.1 Abbott Laboratories
16.1.1 Overviews
16.1.2 Key Persons
16.1.3 Recent Developments
16.1.4 SWOT Analysis
16.1.5 Revenue Analysis
16.2 Astellas Pharma Inc.
16.3 Bristol-Mayers Squibb
16.4 Gilead Sciences
16.5 GlaxoSmithKline Pharmaceuticals Ltd.
16.6 F. Hoffmann-La Roche Ltd.
16.7 Merck & Co. Inc.
16.8 Novartis AG
16.9 Sanofi SA
16.10 Pfizer Inc.
16.11 Takeda Pharmaceuticals
For more information about this report visit https://www.researchandmarkets.com/r/6qydm6
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
